Expression of pituitary tumor-transforming gene 1 during the development of androgen-independent prostate cancer.
- Author:
Xi-Liang CAO
1
;
Xiao-Ming SONG
1
;
Wen-Chao YU
1
;
Yong-Qiang CHEN
2
;
Yang-Yang WEI
2
;
Yong-Liang LIU
2
;
Ke-Quan LU
2
Author Information
- Publication Type:Journal Article
- Keywords: LNCaP cell line; matrix metalloproteinases 2; androgen deprivation therapy; androgen-independent; matrix metalloproteinases 9; pituitary tumor transforming gene 1; prostate cancer
- MeSH: Blotting, Western; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; metabolism; Matrix Metalloproteinase 9; metabolism; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; enzymology; genetics; Securin; genetics
- From: National Journal of Andrology 2016;22(8):686-691
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the expression of pituitary tumor transforming gene 1 (PTTG1) during the transformation of prostate cancer from androgen-dependent (ADPC) to androgen-independent (AIPC).
METHODSWe established an AIPC cell model LNCaP-AI by culturing the androgen-dependent LNCaP cell line in the hormone-deprived medium for over 3 months. The cell model was verified and the PTTG1 expression in the LNCaP cells was detected by Western blot and RT-PCR during hormone deprivation.
RESULTSThe AIPC cell model LNCaP-AI was successfully established. The PTTG1 expression was gradually increased in the LNCaP cells with the prolonged time of hormone deprivation and the expressions of matrix metalloproteinases MMP-2 and -9 were elevated at the same time.
CONCLUSIONSThe expression of PTTG1 is increased gradually in AIPC, which may be a target of gene therapy for advanced prostate cancer.
